U.S. Patent granted to Allinky

Allinky is proud to announce that on August 27th, 2024, the United States Patent and Trademark Office (USPTO) granted a patent for its invention ‘PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA’. This achievement follows the recent success of being awarded a European Patent for the same invention, marking a significant milestone in the company’s global intellectual property strategy and strengthening its competitive position in the U.S. market.

The dual recognition by both the USPTO and the European Patent Office (EPO) reinforces Allinky’s position as a global leader in biotech innovation. Our invention represents a breakthrough in drug development, offering cutting-edge solutions for unmet inflammatory and fibrotic conditions.